Cytokine profile and predictors of the efficacy of genetically engineered biological therapy for psoriasis and psoriatic arthritis: a literature review
https://doi.org/10.33667/2078-5631-2026-3-18-23
Abstract
Psoriasis and psoriatic arthritis (PsA) are recognized as heterogeneous immune-mediated inflammatory disorders with a pronounced systemic component, whose development is driven by complex interactions between innate and adaptive immunity. The IL-23/Th17/IL-17 axis plays a central role in the pathogenesis of psoriatic disease; however, increasing attention is being directed toward non-axis mediators, including IL-6, IL-8, IL-22, IL-33, and IL-35, which reflect tissue specificity and immunological heterogeneity. The introduction of TNF-α and IL-17A inhibitors has significantly improved both cutaneous and articular outcomes; nevertheless, variability in clinical response and secondary loss of efficacy remain substantial challenges. Evidence from clinical and immunological studies demonstrates heterogeneity in the dynamics of circulating cytokines during biologic therapy and underscores the need for reliable predictive biomarkers of treatment response. A comprehensive assessment of cytokine profiles, together with accessible hematological markers of systemic inflammation- particularly the neutrophil-to-lymphocyte ratio (NLR) – may represent a promising approach for disease monitoring and the advancement of personalized therapeutic strategies.
About the Authors
S. R. Redko
Central State Medical Academy of the Administrative Department of the President of the Russian Federation
Russian Federation
Russian Federation
Redko Sofya R., postgraduate student at Dept of Dermatovenereology and Cosmetology
Moscow
N. S. Rudneva
Tula Regional Clinical Dermatovenereological Dispensary
Russian Federation
Russian Federation
Rudneva Natalya S., PhD Med Sci, chief physician, associate professor at Dept of Propaedeutics of Internal Medicine, and the Dermatovenereology Course2, chief freelance specialist dermatovenerologist, cosmetologist at the Ministry of Health of the Tula Region
Tula
References
1. Круглова Л.С., Бакулев А.Л., Коротаева Т.В. Псориаз. Москва: ГЭОТАР-Медиа; 2022. 320 с. ISBN978-5-9704-7105-0. Kruglova L.S., Bakulev A.L., Korotaeva T.V. Psoriasis. Moscow: GEOTAR-Media; 2022. 320 p. ISBN978-5-9704-7105-0. (In Russ.).
2. Parisi R., Iskandar I.Y.K., Kontopantelis E., Augustin M., Griffiths C.E.M., Ashcroft D.M. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369: m1590. https://doi.org/10.1136/bmj.m1590
3. Lembke S., Macfarlane G.J., Jones G.T. The worldwide prevalence of psoriatic arthritis: a systematic review and meta-analysis. Rheumatology (Oxford).2024; 63 (12): 3211–3220. https://doi.org/10.1093/rheumatology/keae198
4. Perez-Chada L.M., Elman S., Villa-Ruiz C., Armstrong A.W., Gottlieb A.B., Merola J.F. Psoriatic arthritis: A comprehensive review for the dermatologist. Part I: Epidemiology, comorbidities, pathogenesis, and diagnosis. J Am Acad Dermatol. 2025; 92 (5): 969–982. https://doi.org/10.1016/j.jaad.2024.03.058
5. Кубанов А.А., Богданова Е.В. и др. Эпидемиология псориаза в Российской Федерации по данным регистра пациентов. Вестник дерматологии и венерологии. 2022; (1): 33–41. https://doi.org/10.25208/vdv1268 Kubanov A.A., Bogdanova E.V., et al. Epidemiology of psoriasis in the Russian Federation according to patient registry data. Bulletin of Dermatology and Venereology. 2022; (1): 33–41. (In Russ.). https://doi.org/10.25208/vdv1268
6. Reich K., Kristensen L.E., Smith S.D., Rich P., Sapin C., Leage S.L. et al. Efficacy and safety of ixekizumab versus adalimumab in biologic-naïve patients with active psoriatic arthritis and moderate-to-severe psoriasis: 52-week results from the SPIRIT-H2H trial. Dermatol Pract Concept. 2022; 12 (2): e2022104. https://doi.org/10.5826/dpc.1202a104
7. Zhang A., Kurtzman D.J.B., Perez-Chada L.M., Merola J.F. Psoriatic arthritis and the dermatologist: an approach to screening and clinical evaluation. Clin Dermatol. 2018; 36 (4): 551–560. https://doi.org/10.1016/j.clindermatol.2018.04.011
8. Smolen J.S., Mease P., Tahir H. et al. Efficacy and safety of ixekizumab versus adalimumab in psoriatic arthritis: final results by week 52. Ann Rheum Dis. 2020;79(10):1310–1319. https://doi.org/10.1136/annrheumdis-2020–217372
9. Gossec L., Kerschbaumer A., Ferreira R.J.O., Aletaha D., Baraliakos X., Bertheussen H. et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024; 83 (6): 706–719. https://doi.org/10.1136/ard-2024–225531
10. Magee C., Jethwa H., FitzGerald O.M., Jadon D.R. Biomarkers predictive of treatment response in psoriasis and psoriatic arthritis: a systematic review. Ther Adv Musculoskelet Dis. 2021; 13: 1759720X211014010. https://doi.org/10.1177/1759720X211014010
11. Schwarz C.W., Loft N., Rasmussen M.K., Nissen C.V., Dam T.N., Egeberg A., Skov L. Predictors of response to biologics in patients with moderate-to-severe psoriasis: a Danish nationwide cohort study. Acta Derm Venereol. 2021; 101 (10): adv00579. https://doi.org/10.2340/actadv.v101.351
12. Liu X.Q., Zhou P.L., Yin X.Y., Wang A.X., Wang D.H., Yang Y., Liu Q. Circulating inflammatory cytokines and psoriasis risk: a systematic review and meta-analysis. PLoS One. 2023; 18 (10): e0293327. https://doi.org/10.1371/journal.pone.0293327
13. Смирнова С.В., Смольникова М.В. Иммунопатогенез псориаза и псориатического артрита. Медицинская иммунология. 2014; 16 (2): 127–138. https://doi.org/10.15789/1563-0625-2014-2-127-138 Smirnova S.V., Smolnikova M.V. Immunopathogenesis of psoriasis and psoriatic arthritis. Medical Immunology. 2014; 16 (2): 127–138. (In Russ.). https://doi.org/10.15789/1563-0625-2014-2-127-138
14. Lowes M.A., Suárez-Fariñas M., Krueger J.G. Immunology of psoriasis. Annu Rev Immunol. 2014; 32: 227–255. https://doi.org/10.1146/annurev-immunol-032713–120225
15. Hawkes J.E., Chan T.C., Krueger J.G. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017; 140 (3): 645–653. https://doi.org/10.1016/j.jaci.2017.07.004
16. McInnes I.B., Mease P.J., Kirkham B. et al. Secukinumab in patients with psoriatic arthritis (FUTURE2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015; 386 (9999): 1137–1146. https://doi.org/10.1016/S0140–6736(15)61134-5
17. Moschetta M., Reale A., Marasco C., Vacca A., Carratù M.R. Therapeutic targeting of the mTOR-signalling pathway in cancer: benefits and limitations. Br J Pharmacol. 2014;171(16):3801–3813. https://doi.org/10.1111/bph.12749
18. Boehncke W. H., Schön M. P. Psoriasis. Lancet. 2015; 386 (9997): 983–994. https://doi.org/10.1016/S0140–6736 (14) 61909-7
19. Nestle F.O., Kaplan D.H., Barker J. Psoriasis. N Engl J Med. 2009; 361 (5): 496–509. https://doi.org/10.1056/NEJMra0804595
20. Chiricozzi A., Romanelli P., Volpe E., Borsellino G., Romanelli M. Scanning the immunopathogenesis of psoriasis. Int J Mol Sci. 2018; 19 (1): 179. https://doi.org/10.3390/ijms19010179
21. Veale D.J., Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018; 391 (10136): 2273–2284. https://doi.org/10.1016/S0140–6736 (18) 30830-4
22. Sieminska I., Pieniawska M., Grzywa T.M. The immunology of psoriasis: current concepts in pathogenesis. Clin Rev Allergy Immunol. 2024; 66 (2): 164–191. https://doi.org/10.1007/s12016-024-08991-7
23. Corbett M., Ramessur R., Marshall D. et al. Biomarkers of systemic treatment response in people with psoriasis: a scoping review. Br J Dermatol. 2022; 187 (4): 494–506. https://doi.org/10.1111/bjd.21677
24. Wolk K., Witte E., Wallace E. et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes. Eur J Immunol. 2006; 36 (5): 1309–1323. https://doi.org/10.1002/eji.200535503
25. Lo Y.H., Wu C.S., Chen Y.T. et al. Serum IL-22 and IL-6 correlations with psoriasis severity and phototherapy response. J Dermatol Sci. 2010; 58 (3): 225–227. https://doi.org/10.1016/j.jdermsci.2010.03.018
26. Olejniczak-Staruch I., Narbutt J., Skibińska M., Lesiak A. Interleukin-22 and –6 decrease under long-term biologic therapy in psoriasis. Adv Dermatol Allergol. 2020; 37 (5): 705–711. https://doi.org/10.5114/ada.2020.101469
27. Arican O., Aral M., Sasmaz S., Ciragil P. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm. 2005; (5): 273–279. https://doi.org/10.1155/MI.2005.273
28. Bai F., Zheng W., Dong Y. et al. Serum levels of adipokines and cytokines in psoriasis patients: a systematic review and meta-analysis. Oncotarget. 2017; 9 (1): 1266–1278. https://doi.org/10.18632/oncotarget.22260
29. Паньшина Н. Н., Шилова Л. Н. Особенности цитокинового профиля у больных псориатическим артритом. Медицинский вестник Северного Кавказа. 2017; (4): 355–358. https://doi.org/10.14300/mnnc.2017.12099 Panshina N.N., Shilova L.N. Features of the cytokine profile in patients with psoriatic arthritis. Medical Bulletin of the North Caucasus. 2017; (4): 355–358. (In Russ.). https://doi.org/10.14300/mnnc.2017.12099
30. Mitsui A., Tada Y., Takahashi T. et al. Serum IL-33 levels are increased in patients with psoriasis. Clin Exp Dermatol. 2016; 41 (2): 183–189. https://doi.org/10.1111/ced.12670
31. Li T., Gu M., Liu P. et al. Clinical significance of decreased interleukin-35 expression in patients with psoriasis. Microbiol Immunol. 2018; 62 (6): 373–379. https://doi.org/10.1111/1348–0421.12605
32. Sakkas L.I., Mavropoulos A., Perricone C., Bogdanos D.P. IL-35: a new immunomodulator in autoimmune rheumatic diseases. Immunol Res. 2018; 66 (3): 305–312. https://doi.org/10.1007/s12026-018-8998-3
33. Zaba L.C., Cardinale I., Gilleaudeau P. et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med. 2007;204(13):3183–3194. https://doi.org/10.1084/jem.20071094
34. Caproni M., Antiga E., Melani L. et al. Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial. J Clin Immunol. 2009; 29 (2): 210–214. https://doi.org/10.1007/s10875-008-9233-0
35. Morita A., Tani Y., Matsumoto K. et al. Assessment of serum biomarkers in patients with plaque psoriasis on secukinumab. J Dermatol. 2020; 47 (5): 452–457. https://doi.org/10.1111/1346–8138.15278
36. Ziolkowska-Banasik D., Pastuszczak M., Zawadzinska-Halat K. et al. Serum IL-18/IL-13 ratio predicts super response to secukinumab in patients with psoriasis. Int J Mol Sci. 2025;26(13):6432. https://doi.org/10.3390/ijms26136432
37. Miyagawa I., Nakayamada S., Ueno M. et al. Impact of serum interleukin-22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis. Arthritis Res Ther. 2022; 24 (1): 86. https://doi.org/10.1186/s13075-022-02771-4
38. Medjedovic L., Vižlin A., Andersch Björkman Y. et al. Impact of brodalumab on serum levels of IL-6, IL-17A, IFN-α, IFN-γ, and TNF-α in patients with psoriasis who failed treatment with TNF-α inhibitors. Int J Mol Sci. 2026; 27 (1): 458. https://doi.org/10.3390/ijms27010458
39. Skougaard M., Søndergaard M.F., Ditlev S.B., Kristensen L.E. Changes in inflammatory cytokines in responders and non-responders to TNFα inhibitor and IL-17A inhibitor in psoriatic arthritis. Int J Mol Sci. 2024; 25 (5): 3002. https://doi.org/10.3390/ijms25053002
40. Furue M., Tsuji G., Mitoma C. et al. Pathogenesis of psoriasis and the development of targeted therapies. J Dermatol Sci. 2018; 92 (3): 217–224. https://doi.org/10.1016/j.jdermsci.2018.08.025
41. Wang W.M., Wu C., Gao Y.M. et al. Neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, and other hematological parameters in psoriasis patients. BMC Immunol. 2021; 22: 64. https://doi.org/10.1186/s12865-021-00454-4
42. Ataseven A., Bilgin A.U., Kurtipek G.S. The importance of neutrophil lymphocyte ratio in patients with psoriasis. Clin Med Res. 2014; 3 (2): 72–75. https://doi.org/10.11648/j.cmr.20140302.17
43. Asahina A., Kubo N., Umezawa Y. et al. Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and mean platelet volume in Japanese patients with psoriasis and psoriatic arthritis: response to therapy with biologics. J Dermatol. 2017; 44 (10): 1112–1121. https://doi.org/10.1111/1346–8138.13875
Review
For citations:
Redko S.R., Rudneva N.S. Cytokine profile and predictors of the efficacy of genetically engineered biological therapy for psoriasis and psoriatic arthritis: a literature review. Medical alphabet. 2026;(3):18-23. (In Russ.) https://doi.org/10.33667/2078-5631-2026-3-18-23
Views:
84
JATS XML
Email this article 